Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir

Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48 Clinical Trial

Official title: Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized Open-label Controlled Trial

Status Recruiting

Clinical Trial Summary

Little is known about efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic ehpatitis B patients who achieved a complete virological response to entecavir and tenofovir. This study aimed to investigate the efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic hepatitis B patients with undetectable heaptitis B virus DNA while on tenofovir plus entecavir combination therapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48

• NCT number: NCT03236610
• Study type: Interventional
• Source: Uijeongbu St. Mary Hospital
• Status: Recruiting
• Phase: Phase 3
• Start date: January 1, 2016
• Completion date: June 30, 2019